Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4852 Target Snapshot

Mitogen-activated protein kinase kinase kinase kinase 5 · SINGLE PROTEIN · Homo sapiens

1,384Compounds
254Assays
22Approved Drugs
1,109.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9Y4K4. Use UniProt Q9Y4K4 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9Y4K4 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mitogen-activated protein kinase kinase kinase kinase 5 as ChEMBL target CHEMBL4852, mapped to UniProt Q9Y4K4. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mitogen-activated protein kinase kinase kinase kinase 5
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4852
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9Y4K4
Mitogen-activated protein kinase kinase kinase kinase 5
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Mitogen-activated protein kinase kinase kinase kinase 5 is the right protein anchor across sources, using UniProt Q9Y4K4 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMitogen-activated protein kinase kinase kinase kinase 5
UniProt AccessionQ9Y4K4
Component TypeProtein
Sequence Length846 aa

Mitogen-activated protein kinase kinase kinase kinase 5

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Mitogen-activated protein kinase kinase kinase kinase 5, mapped to UniProt Q9Y4K4. Sequence length is 846 aa.

Mapped IDQ9Y4K4
Review nameMitogen-activated protein kinase kinase kinase kinase 5
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

22
Approved
16
Phase III
27
Phase II
15
Phase I
Assay Mix

Activity Type Distribution

IC5036.0
KI679.0
EC501.0
KD393.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 9.75 IC50 0.177 Preclinical
CHEMBL1996649 9.7 Ki 0.1995 Preclinical
CHEMBL1999414 9.7 Ki 0.1995 Preclinical
CHEMBL288441 9.52 IC50 0.3 Approved
CHEMBL288441 9.3 Kd 0.5 Approved
CHEMBL1980995 9.2 Ki 0.631 Preclinical
CHEMBL180022 9.19 Kd 0.65 Approved
CHEMBL1979773 9.1 Ki 0.7943 Preclinical
CHEMBL1986851 8.9 Ki 1.259 Preclinical
CHEMBL1970317 8.8 Ki 1.585 Preclinical
Distribution

pChEMBL Value Distribution

58
5.0
131
5.5
119
6.0
77
6.5
71
7.0
35
7.5
26
8.0
2
8.5
4
9.0
6
9.5
pChEMBL
Approved Drugs

Approved Drugs

QUIZARTINIB
CHEMBL576982
Approved 2023
ENTRECTINIB
CHEMBL1983268
Approved 2019
NERATINIB
CHEMBL180022
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
BOSUTINIB
CHEMBL288441
Approved 2012
AXITINIB
CHEMBL1289926
Approved 2012
CRIZOTINIB
CHEMBL601719
Approved 2011
VANDETANIB
CHEMBL24828
Approved 2011
DASATINIB
CHEMBL5416410
Approved 2006
SUNITINIB
CHEMBL535
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
Assay Landscape

Assay Landscape

254
Total Assays
376
Tested Compounds
2
Assay Types
Binding — 253 assays, 115 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 189 52 6.7
assay format 28 3 6.2
cell-based format 21 7 6.1
subcellular format 15 53 5.9
Functional — 1 assays, 376 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 376 6.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine